Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Saturday, June 15, 2024 | Back issues
Courthouse News Service Courthouse News Service

Medical Fraud

A federal class action accuses Amag Pharmaceuticals of unjustly enriching itself by falsely claiming that its overpriced drug Makena (hydroxyprogesterone caproate) prevents preterm births.

SACRAMENTO — A federal class action accuses Amag Pharmaceuticals of unjustly enriching itself by falsely claiming that its overpriced drug Makena (hydroxyprogesterone caproate) prevents preterm births.

Categories / Business, Health, Personal Injury

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...